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Abstract
Background: Epilepsy is the most common neurological disease in veterinary practice. However, contrary to human
medicine, epilepsy classification in veterinary medicine had not been clearly defined until recently. A number of reports
on canine epilepsy have been published, reflecting in part updated proposals from the human epilepsy organization,
the International League Against Epilepsy. In 2015, the International Veterinary Epilepsy Task Force (IVETF) published a
consensus report on the classification and definition of canine epilepsy. The purpose of this retrospective study was to
investigate the etiological distribution, survival time of dogs with idiopathic epilepsy (IdE) and structural epilepsy (StE),
and risk factors for survival time, according to the recently published IVETF classification. We investigated canine cases
with epilepsy that were referred to our teaching hospital in Japan during the past 10 years, and which encompassed a
different breed population from Western countries.
Results: A total of 358 dogs with epilepsy satisfied our etiological study criteria. Of these, 172 dogs (48 %) were classified
as IdE and 76 dogs (21 %) as StE. Of these dogs, 100 dogs (consisting of 65 with IdE and 35 with StE) were included in
our survival study. Median survival time from the initial epileptic seizure in dogs with IdE and StE was 10.4
and 4.5 years, respectively. Median lifespan of dogs with IdE and StE was 13.5 and 10.9 years, respectively.
Multivariable analysis demonstrated that risk factors for survival time in IdE were high seizure frequency
(≥0.3 seizures/month) and focal epileptic seizures.
Conclusions: Focal epileptic seizures were identified as a risk factor for survival time in IdE. Clinicians should carefully
differentiate seizure type as it is difficult to identify focal epileptic seizures. With good seizure control, dogs with IdE can
survive for nearly the same lifespan as the general dog population. Our results using the IVETF classification are similar
to previous studies, although some features were noted in our Japanese canine population (which was composed of
mainly small-breed dogs), including a longer lifespan in dogs with epilepsy and a larger percentage of
meningoencephalomyelitis of unknown origin in dogs with StE.
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Background
Epilepsy is a common chronic and functional brain
disorder in dogs and humans that is characterized by re-
current epileptic seizures. In the veterinary field, classifica-
tion and terminology of epilepsy in part reflects current
proposals from the human epilepsy organization, the
International League Against Epilepsy [1–4]. However, a
consensus on classification and terminology in veterinary
medicine had not until recently been agreed; diagnostic
procedures of epilepsy are slightly different between
humans and animals, therefore routine examinations in
human medicine (e.g., electroencephalogram (EEG) or
functional imaging) have limitations in veterinary medi-
cine. In order to address this problem, the International
Veterinary Epilepsy Task Force (IVETF) was recently
organized from specialists of veterinary neurology and
other neuroscientists. Accordingly, new consensus reports
on canine epilepsy were published in 2015 [5–11].
According to the IVETF consensus, “epilepsy is de-
fined as a brain disease characterized by an enduring
predisposition to generate epileptic seizures” [5]. Conse-
quently, IVETF etiologically classified canine epilepsy
into idiopathic epilepsy (IdE), structural epilepsy (StE),
and unknown cause [5]. Additionally, IdE is further
divided into genetic epilepsy, suspected genetic epilepsy,
and epilepsy of unknown cause. Classification of dogs
into genetic or suspected genetic epilepsy requires
genetic and/or family analysis.
The IVETF criteria for IdE diagnosis is described by a
three-tier system [6]. The tier I confidence level de-
scribes a history of two or more unprovoked epileptic
seizures occurring at least 24 h apart, with an age at
epileptic seizure onset of between 6 months and 6 years,
an unremarkable interictal physical and neurological
examination, and no significant abnormalities on mini-
mum data base (MDB) blood tests and urinalysis. The
tier II confidence level describes unremarkable fasting
and postprandial bile acids, brain magnetic resonance
imaging (MRI), and cerebrospinal fluid (CSF) analysis.
The tier III confidence level describes characteristic EEG
abnormalities for seizure disorders. In addition, the
IVETF consensus recommends performing MRI and
CSF analysis in dogs with the following conditions: age
of initial epileptic seizure onset <6 months or >6 years,
neurological deficits, cluster seizures (CS) or status epi-
lepticus (SE) at initial epileptic seizure onset, and cases
previously diagnosed as presumptive IdE but showing
single antiepileptic drug (AED) resistance.
Because the IVETF classification has only recently
been defined, there have not yet been etiological or sur-
vival studies of canine epilepsy based on this classifica-
tion system. Previous studies of lifespan in dogs with
epilepsy have been reported using different (conven-
tional) classifications. A recent study reported median
lifespan to be 9.2, 5.8, and 7.6 years for dogs with IdE,
StE, and epilepsy from all causes, respectively [12], with
premature death due to epilepsy-related causes. More-
over, some studies have focused on CS [13, 14] and/or
SE [15], and reported that dogs with frequent CS may be
associated with euthanasia [13], while dogs with SE may
have a short survival time [15].
Here, we retrospectively investigated the etiological
distribution of canine cases with epilepsy, which had
been referred to our teaching hospital in Japan (Tokyo)
during the past 10 years (2003–2013). In this study,
distribution of breeds in the canine population was dif-
ferent from Western countries. The purpose of our
study was to classify dogs with epilepsy according to the
recent IVETF classification in 2015, and to investigate
survival time, lifespan, and risk factors influencing sur-
vival time in dogs with IdE and StE.
Methods
Because this was a retrospective and survey study, ethics
for animal use was not requested. Nevertheless, all owners
of the dogs included in this study had agreed to use of
their dogs’ data for academic education and studies, and
had previously signed a consent form on the first presen-
tation to the teaching hospital.
The present study consisted of two components: 1) a
study of the etiological distribution at the time of
epilepsy diagnosis; and 2) a survival study performed
using a questionnaire survey, which included evaluating
risk factors associated with survival.
Definition and inclusion criteria
Definition and inclusion criteria of epilepsy
According to IVETF consensus [6], epilepsy was defined
as cases with a history of at least two unprovoked epileptic
seizures >24 h apart. Cases diagnosed or suspected of
reactive seizures due to metabolic and/or toxic diseases
such as hepatic encephalopathy, hypoglycemia, and elec-
trolyte disturbances were excluded. Cases diagnosed or
suspected of paroxysmal events such as cardiogenic or va-
gotonic syncope, narcolepsy, vestibular attack, and move-
ment disorders by various diagnostic tests (including
semiological videos) were also excluded.
Definition and inclusion criteria of idiopathic epilepsy
IdE was defined as dogs with epilepsy (defined above)
having an age at initial epileptic seizure onset of between
6 months and 6 years, unremarkable interictal physical and
neurological examinations, and no clinically significant
abnormalities on blood tests and urinalysis. Although our
blood tests did not completely match the MDB suggested
by IVETF, most cases corresponded (i.e., complete blood
count (CBC), sodium, potassium, chloride, calcium, phos-
phate, alanine aminotransferase, alkaline phosphatase, total
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bilirubin, urea, creatinine, total protein, albumin, glucose,
cholesterol, and triglycerides), with the exception of bile
acids and ammonia. This was because patients who
showed reactive seizures from metabolic diseases and/or
toxic diseases who were tested for fasting and postprandial
bile acids and ammonia were excluded from this study as
described above. Moreover, urinalysis data were not used
as inclusion criteria for this study, because insufficient
urinalysis had been performed in many cases. Furthermore,
dogs that showed or were clearly suspected of AED-
induced or postictal neurological abnormalities were
included with careful and multiple evaluations by a neur-
ologist (DH). Additionally, we classified dogs that met the
criteria for tier I according to IVETF guidelines except for
age at epileptic seizure onset and having normal MRI and
CSF findings (i.e., tier II) as IdE. Exceptionally, dogs with
interictal neurological deficits and/or abnormal MRI
findings that were suspected as postictal brain damage
were included as IdE under the following conditions:
severe CS or SE cases showing limbic or focal T2-weighted
or fluid attenuated inversion recovery (FLAIR) hyperinten-
sities (images were obtained <10 weeks from the last seiz-
ure [6]), but no neurological deterioration (except for
epileptic seizures) over a period of >1 year.
Definition and inclusion criteria of structural epilepsy
StE was defined as dogs with epilepsy having abnormal
MRI and/or CSF findings, regardless of age at seizure
onset. In addition, StE included cases clinically diagnosed
with degenerative, anomalous, neoplastic, inflammatory,
infectious, traumatic, and vascular diseases (DAMNIT-V
or VITAMIND, except metabolic and toxic) by signal-
ment, clinical course, and MRI/CSF findings. Degenerative
disease was diagnosed by a young age at onset, a subacute
to chronic progressive course, and symmetrical abnormal
MRI findings. Anomalous disease was diagnosed by non-
or less progressive neurological signs with structural fore-
brain anomalies by MRI (e.g., hydrocephalus, arachnoid
cyst, and cortical dysplasia). Neoplastic disease was diag-
nosed by an old age at onset, an acute to chronic progres-
sive course, and recognized intracranial mass formation
by MRI (e.g., meningioma and glioma). Inflammatory
disease (e.g., meningoencephalomyelitis of unknown ori-
gin (MUO)) was diagnosed by typical MRI and/or CSF
findings, including titers for some agents. Traumatic dis-
ease was diagnosed by a history of head trauma with
asymmetrical injury findings by MRI. Vascular disease was
diagnosed by an acute onset, improved clinical course,
and focal (regional) abnormal MRI findings including
hemorrhages. Although some cases (those that had under-
gone surgery or postmortem necropsy) had a definitive
diagnosis, most of these sub-classified categories were
determined clinically (as described) without definitive
(pathological, genetic, or serological) diagnosis.
Classification of seizure type and definition of terms
According to IVETF classification [5], seizure types were
classified into focal epileptic seizures (FES), FES that
evolved into generalized epileptic seizures (FEvG), and
generalized epileptic seizures (GES). Seizure types were
determined by semiological interviews with the owner
(all cases) or recorded ictal video and/or EEG findings
(cases were classified as FES or FEvG if focal spikes were
found). Regarding specific seizure patterns, CS was de-
fined as two or more epileptic seizures within 24 h, and
as SE by a single epileptic seizure lasting more than
5 min, or two or more discrete epileptic seizures without
complete recovery of consciousness.
The seizure frequency of each patient was acquired at
two time-points; at the time of the first presentation at the
teaching hospital as determined from medical records,
and at the time of the last follow-up as determined from
the questionnaire as a continuous variable of mean num-
ber of seizures per month (sz/month).
Survival time was defined as the time period from the
initial epileptic seizure until the date of death or last
follow-up. Lifespan was defined as the time period from
the date of birth until the date of death or last follow-up.
Magnetic resonance imaging and cerebrospinal fluid
analysis
Although the MRI performed in this study did not
adhere to the epilepsy-specific MRI protocol suggested
in the IVETF proposal for the IdE tier II confidence level
[6, 10], all MRI scans included T1-weighted, T2-
weighted, FLAIR, and contrast-enhanced T1-weighted
images in the transverse plane. Images were obtained
using a 1.5-Tesla system [Visart® 1.5 Tesla, Toshiba
Medical System, Tokyo, Japan (between April 2003 and
October 2009)] or 3.0-Tesla system [Signa® HDxt 3.0T,
GE Healthcare, Tokyo, Japan (between October 2009
and March 2013)]. Furthermore, in cases examined by
3.0-Tesla, 3D T1- (pre- and post-contrast) and T2-
weighted images were obtained, with multiplanar recon-
structions provided for review, as suggested in the
epilepsy-specific MRI protocol [10]. All MR images were
reviewed by a neurologist (DH). When CSF analysis was
available, CSF tapping was performed via cisternal punc-
ture following MRI, and analyzed by (at least) cell count,
cytology, and protein measurement. Exceptionally, in
some cases, MRI (using 0.4–1.0-Tesla systems) and CSF
analysis were performed in other institutes before referral
to our teaching hospital. Nevertheless, MRI included the
sequences described above (except for 3D sequences), and
the same CSF analyses were performed.
Etiological distribution study and statistical analysis
Medical records from the Neurology and Neurosurgery
units of the Veterinary Medical Teaching Hospital of
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Nippon Veterinary and Life Science University (Tokyo,
Japan) were searched for dogs that had presented from
April 2003 to March 2013 with a chief complaint of
seizures. In general, our teaching hospital admits referral
cases only. The following data were extracted: (1) breed;
(2) body weight; (3) gender and neuter status; (4) age at
first presentation; (5) age at initial seizure onset; (6)
seizure type; (7) seizure frequency; (8) presence of CS or
SE; (10) interictal neurological findings; (11) MRI/CSF
findings; (12) number and type of AEDs; and (13) other
treatments. After surveying all the cases, those with
reactive seizures or paroxysmal events (non-epileptic
seizures) were excluded, and dogs with epilepsy were
classified into IdE and StE based on our inclusion
criteria (described above). StE cases were further sub-
classified into DAMNIT-V categories based on clinical
diagnosis.
For statistical comparisons between IdE and StE, chi-
squared tests were performed for categorical data (gender,
neuter status, seizure type, CS/SE, multiple AED use) and
Mann–Whitney U tests were performed for continuous
data (body weight and seizure frequency at the time of
first presentation). Values of P < 0.05 were considered
significant. Statistical analyses were performed using the
EZR 1.28 software package (Saitama Medical Center, Jichi
Medical University, Saitama, Japan) [16].
Survival study and statistical analysis
A standardized questionnaire was sent to referring veteri-
narians in March 2014. The questionnaire included current
or changed seizure frequency since start of treatment,
seizure type (if changed), status of treatment (type of AEDs
and other treatments e.g., glucocorticoids, other immuno-
suppressive drugs, decompressive drugs), mortality status
(i.e., dead or alive), and cause and time of death (if applic-
able). Dogs whose survival status (alive or dead) could be
confirmed from questionnaire responses were included in
the survival study.
The Kaplan–Meier method with log-rank test was used
to estimate median survival time and median lifespan for
all epilepsy cases (including IdE and StE), IdE, and StE (in-
cluding sub-classified categories). Dogs alive at the time of
follow-up were censored. Furthermore, the Kaplan–Meier
method with log-rank test was used to estimate median
survival time in all epilepsy cases, IdE, and StE cases
stratified by body weight (median), gender, neuter status,
seizure frequency at the last follow-up, presence of CS
and SE, seizure type, and multiple AED use. In order to
incorporate seizure frequency at the last follow-up into
the log-rank test, it was divided for survival analysis into
<0.3 and ≥0.3 sz/month. This baseline of 0.3 sz/month
was decided from the ‘acceptable seizure frequency’ (less
than one seizure in 3 months) suggested in the IVTEF
proposal [9, 17]. To assess the risk factor for survival time
in all epilepsy cases and IdE, the Cox proportional hazard
model was employed using the forced-entry method. To
avoid multicollinearity, independent variables were used
in the model. All factors were entered into the Cox pro-
portional hazard model. The variables with P values of
<0.3 in the first analysis remained in the final model, and
other variables were removed. The final Cox proportional
hazard analysis was then performed within the remaining
variables. Because the StE group consisted of a small num-
ber of cases that were heterogenous, we excluded StE
cases from the Cox hazard analysis. The P value, hazard
ratio (HR), and confidence interval (CI) were calculated. P
values < 0.05 were considered significant. All survival ana-
lyses were performed using EZR.
Results
Etiological distribution at the time of epilepsy diagnosis
Of 19,193 dogs admitted to the hospital during the study
period, 472 dogs had seizure events (including 5 dogs
(1.0 %) with reactive seizures), and 358 dogs (1.87 %) satis-
fied the definition of epilepsy. Of these 358 dogs, the
following diagnostic tests were performed at the time of
diagnosis: CBC and serum biochemistry profile except bile
acids and ammonia (n = 337), urinalysis (n = 12), MRI (n
= 185), CSF analysis (n = 35), and EEG (n = 7). Addition-
ally, 22 videos of epileptic seizure were acquired from
owners. Consequently, 172 dogs (48.0; 0.90 % of total)
were classified as IdE and 76 (21.2; 0.40 % of total) as StE.
The remaining 110 dogs could not be classified into either
group; of these, 80 dogs had an age at initial epileptic
seizure of <6 months or >6 years, 60 dogs had neuro-
logical deficits, and none had both MRI and CSF analysis
performed. Only one dog with an initial seizure onset at
6.8 years old was included in the IdE category because of
normal MRI and CSF findings. Additionally, four dogs
with postictal brain damage due to SE were judged as IdE
because of >1-year follow-up. Clinical data for all dogs
with epilepsy and the breed distribution in each category
(all epilepsy cases, IdE, and StE) are provided in Tables 1
and 2, respectively.
Regarding adherence to the IVETF diagnostic criteria
for IdE (i.e., three-tier confidence level), in the IdE group,
the complete MDB blood test and urinalysis suggested by
IVETF was performed in 29 dogs and 4 dogs, respectively.
Only two dogs fulfilled the tier I confidence level criteria.
Although MRI was performed for 60 dogs, only 13
received CSF analysis. Therefore, 13 dogs fulfilled the tier
II confidence level criteria (except for fasting and post-
prandial bile acids) but had insufficient MDB for tier I.
Additionally, EEG examination (i.e., tier III confidence
level) was performed in four dogs.
According to IVETF classification, all dogs with IdE
had epilepsy of unknown cause, as no genetic and/or
familial analyses were performed. The breeds, Lagotto
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Romganolo (LGI2 mutation) [18] and Belgian Shepherd
(ADAM23 mutation) [19], which exhibit genetic epi-
lepsy, were not present in this study. However, 53 dogs
(nine breeds) were from the breeds listed as having sus-
pected genetic epilepsy in an IVETF report [7].
In the StE group, MRI was performed for 76 dogs and
13 received CSF analysis. There was a tendency to avoid
CSF tapping in anomalous and neoplastic diseases due
to suspected elevated intracranial pressure, and similarly,
in inflammatory disease in small-breed dogs with Chiari-
like malformations. The StE group included 28 dogs
(36.9 %) with inflammatory disease (MUO), 22 (28.9 %)
with neoplastic disease, 9 (11.8 %) with anomalous
disease, 6 (7.9 %) with vascular disease, and 1 (1.3 %)
with traumatic disease. The remaining 10 dogs (13.2 %)
were not possible to classify because of coexisting
lesions.
When comparing clinical and demographic features
of the IdE and StE groups, presence of CS (IdE, 31 %
vs. StE, 55 %; P = 0.0004), FES (IdE, 30 % vs. StE, 13 %;
P = 0.009), GES (IdE, 46 % vs. StE, 74 %; P < 0.0001),
and seizure frequency at the time of first presentation
(P < 0.0001) were significantly different in incidence
(Table 1). Body weight did not differ between the two
groups (P = 0.36). Additionally, there was no signifi-
cant difference in gender (P = 0.12), neuter status (P =
0.89), presence of SE (P = 0.08), FEvG (P = 0.07), and
multiple AED use (P = 0.69).
Table 1 Clinical data at the time of diagnosis for dogs with epilepsy, idiopathic, and structural epilepsy
Variables Number of dogs
Epilepsy (n = 358) IdE (n = 172) StE (n = 76)
Gender
Male [Neuter] 193 (54 %) [71 (20 %)] 97 (56 %) [37 (22 %)] 34 (45 %) [14 (18 %)]
Female [Neuter] 165 (46 %) [79 (22 %)] 75 (44 %) [41 (24 %)] 42 (55 %) [16 (21 %)]
Body weight (kg)
Median 6.0 6.2 5.9
Range 1.0–54.0 1.3–37.8 1.0–39.5
Age at initial seizure onset (years)
Median 3.6 2.5 5.5
Range 0.1–14.4 0.5–6.8 0.2–13.9
Neurological
Normal or unremarkable 117 (33 %) 170 (99 %) 24 (33 %)
Deficits 241 (67 %) 2 (1 %) 52 (67 %)
Seizure frequency at first presentation (sz/month)
Median 2.0 1.2 4.0*
Range 0.1–37.0 0.1–37.0 0.1–30.0
Seizure type
FES 93 (26 %) 52 (30 %)* 10 (13 %)
GES 190 (53 %) 78 (46 %) 56 (74 %)*
FEvG 75 (21 %) 42 (24 %) 10 (13 %)
Specific seizure pattern
CS 141 (39 %) 53 (31 %) 42 (54 %)*
SE 71 (20 %) 31 (18 %) 22 (29 %)
AEDs used at first presentation
None 180 (51 %) 99 (58 %) 28 (37 %)
Monotherapy 137 (38 %) 55 (32 %) 38 (50 %)
Polytherapy 41 (11 %) 18 (10 %) 10 (13 %)
Using other treatment
No 281 (78 %) 159 (92 %) 30 (41 %)
Yes 77 (22 %) 13 (8 %) 46 (59 %)
IdE idiopathic epilepsy, StE structural epilepsy, MR magnetic resonance, sz seizure, FES focal epileptic seizure, GES generalized epileptic seizure, FEvG focal epileptic
seizure evolving into generalized seizures, CS cluster seizures, SE status epilepticus, AED antiepileptic drug. *P < 0.05 (chi-squared test)
Hamamoto et al. BMC Veterinary Research  (2016) 12:248 Page 5 of 14
Table 2 Number and breed distribution of dogs with epilepsy, idiopathic, and structural epilepsy
Epilepsy (n = 358) IdE (n = 172) StE (n = 76)
Breed n Breed n Breed n
Chihuahua 54 Chihuahua 27 Chihuahua 15
Miniature Dachshund 36 Miniature Dachshund 18 Mixed-breed 7
Mixed-breed 28 Yorkshire Terrier 14 Miniature Dachshund 5
Yorkshire Terrier 24 Toy Poodle 13 Toy Poodle
Toy Poodle 23 Labrador Retriever 10 Pug
Labrador Retriever 17 Mixed-breed 9 Shih Tzu
Shih Tzu 15 Miniature Schnauzer 7 Golden Retriever 4
Pomeranian 14 CKCS Papillon
Pug 13 Welsh Corgi 6 Welsh Corgi 3
CKCS 12 Golden Retriever Labrador Retriever 2
Welsh Corgi 12 Shetland Sheepdog Pomeranian
Golden Retriever 11 Pug 5 Boston Terrier
Shetland Sheepdog 10 Pomeranian 4 French Bulldog
Miniature Schnauzer 9 Papillon Shiba Inu
Papillon 8 Japanese Spitz Petit Basset Griffon Vendeen
Shiba Inu 7 American Cocker Spaniel 3 Yorkshire Terrier 1
French Bulldog 6 French Bulldog Miniature Schnauzer
Maltese 5 Shiba Inu Shetland Sheepdog
Beagle 4 Beagle CKCS
Boston Terrier Boston Terrier 2 Beagle
Japanese Spitz Maltese Boxer
American Cocker Spaniel 3 Italian Greyhound Pekingese
Bulldog Bulldog West Highland White Terrier
Cairn Terrier Shih Tzu 1 Cairn Terrier
Italian Greyhound Irish Setter Bernese Mountain Dog
Pekingese 2 Sealyham Terrier Maltese
Petit Basset Griffon Vendeen Siberian Husky
Siberian Husky Miniature Poodle
Afghan Hound 1 Afghan Hound
Australian Shepherd English Cocker Spaniel
Basset Hound Volpino Nano Bianco
Bernese Mountain Dog Australian Shepherd
Bichon Frise Dalmatian
Bolognese Hokkaido Dog
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Survival study
Of the 358 dogs with epilepsy that were included in the
etiological study, we received 133 replies, of which 100
cases (consisting of 65 dogs with IdE and 35 dogs with
StE) satisfied our survival analysis criteria. The results
for each category of the survival study are described
below.
All epilepsy cases (idiopathic epilepsy and structural
epilepsy)
Of the 100 dogs with epilepsy, 51 dogs were alive at the
end of the study period (March 2014), while 49 had died.
Median lifespan was 13.0 years (156.6 months; 95 % CI,
131.1–181.6 months) and median survival time was
10.1 years (120.9 months; 95 % CI, 88.1–136.1 months).
Lifespan and survival time of dogs with idiopathic
epilepsy
At the end of the study period (March 2014), 39 dogs
were alive and 26 had died. Median lifespan and survival
time were 13.5 years (162.0 months; 95 % CI, 138.6–
182.5 months) and 10.4 years (125.4 months; 95 % CI,
106.8–143.0 months), respectively. Kaplan–Meier curves
of survival time and lifespan for IdE are shown (Figs. 1
and 2, respectively).
There were no cases of euthanasia, and two dogs
were thought to have died because of sudden unex-
pected death in epilepsy (SUDEP) after an epileptic
seizure. These dogs were a Boston Terrier and a
mixed-breed dog, and were 6.1 and 7.3 years old at
the time of death, respectively. Both dogs had high
seizure frequencies (≥4 sz/month), despite AED treat-
ment using zonisamide and phenobarbital-potassium
bromide, respectively. The Boston Terrier became
dyspneic after a single FEvG and subsequently died,
while the mixed-breed dog died suddenly after a sin-
gle GES.
Lifespan and survival time of dogs with structural epilepsy
At the end of the study period (March 2014), 12 dogs
were alive and 23 had died. Of those that died, 7 dogs
(including 4 euthanized cases) had died because of
uncontrolled epileptic seizures, 3 had died because of
other diseases (e.g., intraoral melanoma and degenerative
myelopathy), and 13 had died for unknown reasons.
Median lifespan was 10.9 years (130.2 months; 95 % CI,
102.6–182.6 months) and median survival time was
4.5 years (54.1 months; 95 % CI, 20.1–121.9 months).
Kaplan–Meier curves of survival time and lifespan are
shown (Figs. 1 and 2, respectively).
Detailed sub-classification information is summarized in
Table 3. There were no cases of infectious meningo-
encephalitis, therefore all inflammatory disease cases were
clinically diagnosed as MUO. In addition to AED therapy,
immunosuppressive treatments consisted of glucocorticoid








West Highland White Terrier
Wirehaired Fox Terrier
IdE idiopathic epilepsy, StE structural epilepsy, CKCS Cavalier King Charles Spaniel
Fig. 1 Kaplan–Meier curve of survival time in dogs with idiopathic
and structural epilepsy. Survival time between the groups was
significant (P = 0.00003). Hash marks indicate censored data. IdE
idiopathic epilepsy, StE structural epilepsy
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and cyclosporine, and were administered to all dogs with
MUO. Of 12 dogs with neoplastic disease, 2 had surgery
and histopathological diagnoses of meningioma and osteo-
sarcoma. Additional radiation therapy was performed in
the dog with osteosarcoma. All dogs with neoplastic
disease were treated using AEDs and decompression medi-
cations (e.g., glucocorticoid, glycerin, mannitol). Hydro-
cephalus was the most common anomalous disease (n = 4);
these dogs received decompression medications as well as
AED therapy (there were no surgical cases). The other
anomalous diseases were polymicrogyria (n = 1), porence-
phaly (n = 1), diverticulum (n = 1), and morphological
aberration of the olfactory bulb (n = 1); these cases were
treated with AEDs and symptomatic therapy. Similarly,
dogs with vascular disease received AEDs and symptomatic
treatment. There were significant differences in survival
time (P < 0.05) among the three sub-classifications (anomal-
ous, inflammatory, and neoplastic disease), while there was
no significant difference in lifespan. Kaplan–Meier curves
for each group are shown (Figs. 3 and 4).
Comparing median survival time between IdE and StE
groups, dogs with IdE had a significantly longer survival
time than dogs with StE (P < 0.001) (Fig. 1). However,
there was no significant difference in lifespan between
these two groups (Fig. 2).
Risk factors for survival time analysis
Of the 100 dogs with epilepsy in the survival analysis,
six (including one with IdE and five with StE) were
removed from the analysis of risk factors for survival
time because of insufficient responses to the question-
naire. Clinical data from medical records and question-
naire responses are provided in Table 4, with the breed
distribution in each category provided in Table 5. AED
treatment choices during the clinical course in each
group were obtained from questionnaire responses, and
are shown in Table 6.
Log-rank test results are shown in Table 7. In all
epilepsy cases and IdE, the survival time of dogs with a
seizure frequency of ≥0.3 sz/month was significantly
shorter compared with those with frequency <0.3 sz/
month. Cox proportional hazards for multivariable ana-
lysis showed that a seizure frequency of ≥0.3 sz/month
(P = 0.00005, HR, 5.26, 95 % CI 2.37–11.70) in the all
epilepsy group, and a seizure frequency of ≥0.3 sz/month
(P = 0.0005, HR, 9.80, 95 % CI 2.70–35.52) and FES (P =
0.04, HR, 3.99, 95 % CI 1.05–15.17) in the IdE group
were significantly negatively correlated with survival
time. No significant differences were detected with the
other risk factors in all epilepsy group and IdE.
Fig. 2 Kaplan–Meier curve of lifespan in dogs with idiopathic and
structural epilepsy. There was no significant difference in lifespan
between the two groups (P = 0.11). Hash marks indicate censored
data. IdE idiopathic epilepsy, StE structural epilepsy
Table 3 Survival outcome of dogs with structural epilepsy by
sub-classification
Variables Survival time (years) Lifespan (years)
n (dead) Median 95 % CI Median 95 % CI
Neoplastic 12 (11) 1.1 0.3–6.7 10.8 7.5–11.6
Inflammatory 11 (9) 4.5 1.3–∞ 8.2 3.6–11.6
Anomalous 8 (1) NA 5.6–∞ NA 8.9–∞
Vascular 2 (1) 10.4 ∞–∞ 16.9 ∞–∞
Unclassified 2 (1) 3.3 3.3–∞ 7.6 7.6–∞
95 % CI 95 % confidence interval, NA not available
Fig. 3 Kaplan–Meier curve of survival time in dogs with structural
epilepsy caused by anomalous/inflammatory/neoplastic disease.
Survival time among the three groups was significant (P = 0.02).
Hash marks indicate censored data
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Discussion
This study is the first report on the etiology of canine
epilepsy using the IVETF classification of 2015. We
found that the prevalence of epilepsy was approximately
1.9 % in all dogs that presented to the teaching hospital
(referrals only), and 0.9 and 0.4 % for IdE and StE, re-
spectively. These percentages are similar to previous
studies reporting 1–2.6 % for epilepsy in veterinary refer-
ral clinics, and 0.5–5 % for IdE in primary clinics [7].
These findings suggest that differences in breeds or
countries are not associated with prevalence of epilepsy.
Median survival time in the IdE group (10.4 years) was
longer than in the StE group (4.5 years), which is sup-
ported by previous studies (IdE, 9.2 years and StE,
5.8 years [12]; IdE, 10.5 years and StE, 3.4 years [20]).
Additionally, median lifespan in all epilepsy cases (IdE
and StE), IdE, and StE were 13.0, 13.5, and 10.9 years,
respectively. Previous studies reported median lifespans
in dogs with epilepsy, including all sub-types (i.e., IdE,
StE, and unknown cause), of 7.6 years [12] and 7.0 years
[21], which are clearly exceeded by the present study.
A reason for this discrepancy may be the number of
euthanized dogs: in our study, only 4/100 dogs were eu-
thanized for epilepsy-related causes, whereas 49/81 [12]
and 24/63 [21] dogs were euthanized in the previous
studies. Moreover, all euthanized dogs in the present
study were StE cases. In the previous study, it was
suggested that euthanasia was chosen in many cases be-
cause of quality of life (QOL) degradation due to uncon-
trolled epileptic seizures [22]. Certainly, in our study,
euthanized dogs appeared to have a lower QOL because
of uncontrolled seizures. However, the owners (especially
those of dogs with IdE) had a tendency to refuse euthan-
asia (and also necropsy) because euthanasia is regarded
negatively by the majority of Japanese people.
Another possibility is that companion dogs in Japan
have longer lifespans than those in Western countries.
Inoue et al. (2015) reported a life expectancy of 13.7 years
for dogs in Japan [23]. Our study shows that the median
lifespan of dogs with IdE is as long as companion dogs in
Japan. In contrast, previous studies reported that the
median lifespan in companion dogs in Denmark [24] and
median longevity in England [25] were 10.0 and 12.0 years,
respectively. The breed population of general companion
dogs and/or dogs with epilepsy in Denmark included a
great number of large-breed dogs such as German
Shepherd and Labrador Retriever. Our present study (and
also the previously cited Japanese data [23]) is composed
of many small-breed dogs such as Chihuahua, Toy Poodle,
and Miniature Dachshund, reflecting the current feature
of breed populations in Japan. In general, the lifespan of
large-breed dogs is shorter than small-breed dogs [26].
Therefore, this difference in breed populations between
Western countries and Japan may also influence the
lifespan of dogs with epilepsy.
Regarding risk factors for survival time in IdE, the
presence of FES was found to be significantly associated
with reduced survival time in the present study; how-
ever, this has not been found in previous studies [21].
Recently, Packer et al. (2015) reported that when classi-
fying seizures into seizure types, FES was the least
agreed upon classification between veterinarians and
neurology specialists [27]. Therefore, it appears difficult
to detect FES in animals for veterinarians, let alone for
owners. Furthermore, in experimental studies of kindling
and/or kainic acid, recurrent FES induces more severe
seizure frequency (i.e., kindling phenomenon) and seiz-
ure pattern (e.g., CS, SE, and/or secondary generaliza-
tions), which results in neuronal loss and/or secondary
epileptogenesis such as mirror focus [28–31]. Thus, we
urge practitioners not to think of FES as inferior to GES,
and FES should be treated appropriately even if the
apparent symptoms are short or subtle. In this regard,
EEG may be useful to differentiate FES and GES,
although EEG use in veterinary medicine is not com-
mon, and its availability and standardized methodology
have not yet been well established.
Additionally, we found that a seizure frequency of ≥0.3
sz/month was a risk factor for reduced survival time in IdE.
Death or euthanasia in dogs with epilepsy is associated with
unacceptable epileptic seizure control, which shortens
survival time compared with other causes [21]. As men-
tioned above, no case with IdE was euthanized in our study.
Therefore, our result indicates that a risk factor for reduced
survival time in IdE includes seizure frequency (≥0.3 sz/
month), regardless of euthanasia. In addition, we showed
Fig. 4 Kaplan–Meier curve of lifespan in dogs with structural
epilepsy caused by anomalous/inflammatory/neoplastic disease.
There was no significant difference in lifespan among the three
groups (P = 0.07). Hash marks indicate censored data
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that use of multiple AEDs (polytherapy) was not a risk
factor affecting survival time in IdE. The IVETF proposal
states that the effect of drug-resistant epilepsy on outcome
is not precisely understood [9]. Furthermore, some studies
[12, 32] have shown that survival of dogs receiving multiple
AED treatments does not differ significantly from that of
dogs receiving single AED treatment (monotherapy). These
results suggest that multiple AED treatment may not
directly influence survival time. Therefore, we assume that
a high seizure frequency (≥0.3 sz/month) is a risk factor for
reduced survival time regardless of whether dogs with IdE
receive polytherapy.
In our study, two dogs were thought to have died due to
SUDEP. A few studies have reported SUDEP in veterinary
medicine [33, 34], but its mechanisms remain unknown.
In humans, patients at highest risk for SUDEP show oc-
currence of generalized tonic-clonic seizures, poor seizure
control, a young age, and multiple AED treatment [35].
Here, the two dogs with suspected SUDEP died at a rela-
tively young age (6.1 and 7.3 years) and had a very high
epileptic seizure frequency (≥1 sz/week) with a poor
response to at least one AED treatment. Although there
had only been very small numbers reported, the risk of
SUDEP in dogs is proposed to be similar to humans. In
addition, canine SUDEP was previously reported in an
Akita-inu [33] and Labrador Retriever [34], while here it
was a Boston Terrier and a mixed-breed dog. Indeed, it is
likely that SUDEP may occur in various breeds.
Table 4 Clinical data for dogs with idiopathic and structural epilepsy included in the multivariable analysis
Variables Number of dogs
All epilepsy cases (n = 94) IdE (n = 64) StE (n = 30)
Gender
Male [Neuter] 52 (55 %) [24 (26 %)] 37 (58 %) [18 (28 %)] 15 (50 %) [6 (20 %)]
Female [Neuter] 42 (45 %) [17 (18 %)] 27 (42 %) [11 (17 %)] 15 (50 %) [6 (20 %)]
Body weight (kg)
Median 6.6 7.0 6.1
Range 1.3–35.0 1.3–31.0 2.0–35.0
Age at initial seizure onset (years)
Median 3.1 2.7 6.0
Range 0.4–10.0 0.6–6.8 0.4–10.0
Neurological
Normal or unremarkable 71 (76 %) 62 (97 %) 9 (30 %)
Deficits 23 (24 %) 2 (3 %) 21 (70 %)
Seizure frequency at last follow-up (sz/month)
Median 3.3 2.5 4.0
Range 0.1–20.0 0.1–20.0 0.1–10.0
Seizure type
FES 20 (21 %) 15 (23 %) 5 (17 %)
GES 51 (55 %) 30 (47 %) 21 (70 %)
FEvG 23 (24 %) 19 (30 %) 4 (13 %)
Specific seizure pattern
CS 43 (46 %) 26 (41 %) 17 (57 %)
SE 16 (17 %) 13 (20 %) 3 (10 %)
Using AEDs at last follow-up
None 46 (49 %) 37 (58 %) 11 (37 %)
Monotherapy 35 (37 %) 18 (28 %) 10 (33 %)
Polytherapy 13 (14 %) 9 (14 %) 9 (30 %)
Using other treatment
No 69 (73 %) 60 (94 %) 9 (30 %)
Yes 25 (27 %) 4 (6 %) 21 (70 %)
IdE idiopathic epilepsy, StE structural epilepsy, MR magnetic resonance, sz seizure, FES focal epileptic seizure, GES generalized epileptic seizure, FEvG focal epileptic
seizure evolving into generalized epileptic seizures, CS cluster seizures, SE status epilepticus, AED antiepileptic drug
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In sub-classified StE, there was a significant difference
in survival time among the three groups (anomalous,
inflammatory, and neoplastic disease). The log-rank test
and Kaplan–Meier method showed that >80 % of dogs
with anomalous disease were alive over 5 years after the
initial epileptic seizure onset. Consequently, if a suitable
treatment (including AED therapy) is acceptable, StE
due to anomalous disease might not be a risk factor for
reduced survival time, compared with neoplastic and
inflammatory disease. Nevertheless, survival time is vari-
able depending on the type or severity of malformation
as well as seizure severity. In contrast, median survival
time in neoplastic and inflammatory disease was 13.7
and 54.1 months, respectively. Previously, median sur-
vival time in dogs with neoplastic disease that received
symptomatic treatment, and inflammatory disease that
received immunosuppressive treatment, were reported
as approximately 2.2–23.3 months [35] and 77.5 months
[36], respectively. Therefore, it is important for survival
of dogs with StE to recognize sub-classification by sig-
nalment, clinical course, and MRI/CSF findings. Because
the StE group was composed of various diseases and had
some limitations as described below, we did not perform
risk factor analysis for survival time in StE cases. How-
ever, a seizure frequency of ≥0.3 sz/month was found to
be a risk factor for reduced survival time in all epilepsy
cases, including StE. This may suggest that seizure
control is also important for survival in StE, as well as
specific therapies for causative disease.
We observed significant differences in prevalence of
FES, GES, and CS between the IdE and StE groups. A
previous study stated that it is not possible to differenti-
ate between IdE and StE based on seizure type, but that
FES is more suggestive of StE [37]. FES is frequently
caused by neoplastic disease, which is probably due to
the lesion location being mainly single and focal. Never-
theless, we observed significantly more FES in the IdE
group (30 %) than the StE group (13 %). Additionally,
breeds in our StE group were different (i.e., the majority
were small-breed dogs, as mentioned above) compared
with previous reports [37–39], which included many
large dog breeds such as Boxer, Labrador Retriever, and
German Shepherd. In particular, 74.2 % of Boxers pre-
senting with epileptic seizures had asymmetrical brain
lesions, and many cases were associated with neoplastic
disease [39]. In previous studies, the prevalence of neo-
plastic and inflammatory disease in StE was 22–72 and
7–37 %, respectively [37, 38, 40, 41]. In contrast, in our
Table 5 Number and breed distribution of dogs with
idiopathic/structural epilepsy included in the multivariable
analysis
IdE (n = 64) StE (n = 30)
Breed n Breed n
Chihuahua 8 Chihuahua 5
Toy Poodle 6 Miniature Dachshund 3
Mixed-breed 5 Mixed-breed
Yorkshire Terrier Welsh Corgi
Labrador Retriever 4 Labrador Retriever 2
Welsh Corgi Papillon
Golden Retriever 3 Pug
Miniature Dachshund Shih Tzu
Miniature Schnauzer Boston Terrier 1
American Cocker Spaniel 2 Boxer















IdE idiopathic epilepsy, StE structural epilepsy, CKCS Cavalier King
Charles Spaniel
Table 6 Antiepileptic drug choices in the multivariable analysis






PB + ZNS 2 0
PB + KBr 5 3
ZNS + KBr 10 2
ZNS + DZP 1 0
PB + KBr + ZNS 8 0
PB + KBr + GBP 0 1
PB + ZNS + CZP 1 0
PB + KBr + ZNS + GBP 0 1
PB + KBr + ZNS + LEV 0 1
No AEDs 19 7
AEDs antiepileptic drugs, IdE idiopathic epilepsy, StE structural epilepsy, PB
phenobarbital, ZNS zonisamide, KBr potassium bromide, DZP diazepam, GBP
gabapentin, CZP clonazepam, LEV levetiracetam
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study, StE included many small dog breeds such as Chi-
huahua, Miniature Dachshund, Toy Poodle, Pug, and
Shih Tzu, which show a predisposition to MUO. Fur-
thermore, only one Boxer was included in our study.
Consequently, prevalence of neoplastic and inflamma-
tory disease in our study was 28.2 and 35.9 %, respect-
ively. A previous study reported that the major epileptic
seizure type in dogs with inflammatory disease is GES
[42]. Because many MUO cases implicate multifocal
pathological lesions, GES (or FEvG) may frequently de-
velop compared with FES. Therefore, it is difficult to use
seizure type to diagnose StE in all cases, and it is
necessary to investigate prevalence in various countries
because breeds vary according to community. In con-
trast, we observed significantly more CS development in
the StE group (55 %) compared with the IdE group
(31 %). This is similar to a previous study (IdE, 45.2 %
vs. StE, 65.6 % [34]). The IVETF recommends that MRI
and CSF analysis are performed in dogs with CS at
epileptic seizure onset [6]. Our result supports this
recommendation.
There were some limitations to our study. Because this
was a retrospective study, blood tests, urinalysis, genetic
and/or familial analysis according to the IVETF consen-
sus [6] were not fulfilled in most dogs with IdE. Further-
more, MRI in our study did not correspond to the
epilepsy-specific MRI protocol suggested by IVETF [10].
Although we made efforts to follow the IVETF consen-
sus as much as possible, we had to exclude 110 dogs
with epilepsy that did not satisfy the criteria e.g., our
initial cohort included many dogs that had an initial
epileptic seizure onset at <6 months or >6 years and/or
showed neurological deficits but were not examined by
MRI or CSF analysis due to various reasons such as
complications in the dogs and economic compliance of
owners. Of course the IVETF consensus aims to
standardize future worldwide studies, and researchers
and practitioners should follow its proposals; however, it
Table 7 Log-rank test results for dogs with idiopathic and structural epilepsy
Variables All epilepsy cases (years) IdE (years) StE (years)
n (dead) median (95 % CI) P value n (dead) median (95 % CI) P value n (dead) median (95 % CI) P value
Gender
Male 52 (30) 8.9 (5.6–11.8) 0.26 37 (18) 11.3 (7.3–12.6) 0.45 15 (12) 4.5 (0.4–10.4) 0.20
Female 42 (13) 10.1 (9.2–∞) 27 (7) 10.1 (9.2–∞) 15 (6) NA (1.9–∞)
Status of neuter
Intact 53 (26) 10.2 (8.1–11.8) 0.31 35 (15) 10.4 (8.9–14.5) 0.31 18 (11) 10.2 (1.3–∞) 0.46
Neuter 41 (17) 9.3 (6.3–∞) 29 (10) 9.3 (6.3–∞) 12 (7) 6.7 (0.4–∞)
Body weight
< 6.6 kg 47 (20) 10.2 (6.7–14.5) 0.26 31 (11) 11.9 (7.5–∞) 0.28 16 (9) 6.7 (3.3–∞) 0.27
≥ 6.6 kg 47 (23) 9.3 (7.1–10.4) 33 (14) 10.1 (7.3–∞) 14 (9) 4.0 (0.4–∞)
Seizure frequency at last follow-up
< 0.3 sz/month 48 (16) 11.8 (10.4–14.5) <0.01 37 (11) 11.9 (11.3–14.5) <0.01 11 (5) 10.4 (0.58–∞) 0.06
≥ 0.3 sz/month 46 (27) 7.3 (4.5–9.2) 27 (14) 8.9 (5.3–10.1) 19 (13) 4.5 (1.2–∞)
Epileptic seizure type
FES 20 (6) 8.9 (3.3–∞) 0.77 15 (4) 8.9 (2.9–∞) 0.20 5 (2) NA (0.2–∞) 0.89
GES 51 (26) 10.4 (7.3–11.9) 30 (12) 11.3 (10.1–14.5) 21 (14) 5.6 (1.2–10.4)
FEvG 23 (11) 8.1 (6.3–∞) 19 (9) 9.2 (5.3–∞) 4 (2) 6.7 (6.7–∞)
Development of CS
Yes 43 (22) 9.2 (4.1–11.3) 0.06 26 (11) 10.4 (4.1–∞) 0.21 17 (11) 4.5 (1.1–∞) 0.18
No 51 (21) 10.1 (8.1–11.9) 38 (14) 10.1 (8.1–14.5) 13 (7) 6.7 (3.3–∞)
Development of SE
Yes 16 (9) 10.1 (4.1–11.9) 0.93 13 (7) 10.1 (4.1–∞) 0.42 3 (2) 10.4 (3.3–∞) 0.54
No 78 (34) 10.2 (7.5–11.8) 51 (18) 10.4 (8.9–∞) 27 (16) 6.7 (1.3–∞)
Using AEDs at last follow-up
None or monotherapy 58 (26) 10.4 (7.1–12.6) 0.48 37 (14) 11.9 (7.5–14.5) 0.29 22 (12) 5.6 (1.3–∞) 0.50
Polytherapy 36 (17) 9.3 (6.7–10.4) 27 (11) 9.3 (7.3–11.3) 8 (6) 6.7 (1.1–∞)
IdE idiopathic epilepsy, StE structural epilepsy, 95 % CI 95 % confidence interval, GES generalized epileptic seizure, FES focal epileptic seizure, sz seizure, FEvG focal
epileptic seizure evolving into generalized epileptic seizures, CS cluster seizures, SE epilepticus status, AED antiepileptic drug, NA not available
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may be difficult for a retrospective study to completely
comply with IVETF criteria. Additionally, because histo-
pathological examination was not performed in most dogs
with StE, its sub-classification was evaluated by signalment,
clinical course, and MRI/CSF findings. Therefore, our
etiological and survival study of dogs with StE may have
not been accurately evaluated. Furthermore, the StE group
in the present study was a very heterogeneous group with
multiple diseases, and had a small number of cases in each
disease category. Therefore, statistical power to detect
significant association was thought to be low. The risk
factors for survival time in StE may be found in a larger
study, or a more homogeneous population.
Conclusions
Our study indicates that dogs with well controlled IdE
will survive as long as the lifespan of general pet dogs in
Japan. In contrast to previous studies from Western
countries, many small-breed dogs were included in our
study and may have contributed to our findings of a long
survival time and lifespan. However, we identified a high
seizure frequency (>0.3 sz/month) and FES as risk
factors for survival time in dogs with IdE. Furthermore,
our study shows that survival time of dogs with StE is
shorter than that of dogs with IdE. In particular, StE due
to neoplastic and inflammatory disease is associated with
a short survival time. In contrast to Western countries,
our Japanese study found that inflammatory disease is
more prevalent than neoplastic disease. If dogs exhibit
onset of their initial epileptic seizure at a young to
middle age (i.e., similar to IdE), it is important to differ-
entiate between StE by inflammatory disease and IdE,
especially within regions where small-breed dogs are
popular.
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